Schlosser Mario, President of Technology and CTO, has been a persistent seller of Oscar Health (OSCR) stock while accumulating only compensatory awards in Duolingo (DUOL). Across 45 Form 4 filings spanning two companies, his open-market sales totaled $52.26 million with zero open-market purchases, a decisively one-sided pattern. The selling accelerated in late June 2026, when a cluster of 12 OSCR sales on June 23 alone brought in roughly $28.7 million, including individual transactions of $17.49 million and $8.31 million. Additional sales on July 1 added another $1.48 million, and smaller dispositions occurred on June 2 and March 2, 2026, ranging from roughly $217,000 to $531,000. The June 23 filings also included option exercises (code M) and derivative conversions (code C) valued at zero, indicating the sales were tied to the liquidation of previously held equity rather than new cash outlays.
The only non-sale activity in the recent window was a DUOL grant on July 10, 2026, valued at $17,466.40, and a zero-value award on June 3, 2026. These are compensation events (code A), not conviction purchases, and they represent the entirety of his DUOL holdings activity. No open-market buys appear anywhere in the filing history, meaning every discretionary transaction was a sale. The concentration of OSCR disposals—17 recent sells against zero buys—suggests a systematic reduction of that position, with the largest single-day liquidation occurring on June 23. While the filings do not indicate motive, the magnitude and timing of the sales, particularly the multi-million-dollar blocks, mark a notable shift in his disclosed exposure to Oscar Health.
AI-assisted summary